Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo"

Comparative Clinical and Histopathological Study of Microneedling With Topical Minoxidil 5% Versus Microneedling With Topical Minoxidil 5% Combined With Narrow-Band Ultraviolet B Phototherapy in the Treatment of Stable Vitiligo

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07548918

Enrollment

Registered

2026-04-23

Start date

2026-05-20

Completion date

2027-10-15

Last updated

2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo - Macular Depigmentation

Brief summary

This study is a randomized controlled trial comparing microneedling with topical minoxidil 5% versus microneedling with minoxidil combined with NB-UVB phototherapy in stable vitiligo. It aims to evaluate both clinical and histopathological outcomes in 30 patients with non-segmental stable vitiligo. Vitiligo is a chronic depigmenting disorder caused by melanocyte destruction with significant psychosocial impact. The study also investigates immunohistochemical changes, particularly Wnt/β-catenin signaling expression in lesional skin. The combination therapy is expected to enhance repigmentation by improving melanocyte activation, drug delivery, and angiogenesis

Interventions

COMBINATION_PRODUCTmicroneedling with minoxidil 5% and NBUVB

Micronnedlin depth 1% then topical Minoxidil5% and Narrow Band UVB

COMBINATION_PRODUCTMicroneedling with Minoxidil5%

Microneedling with topical Minoxidil 5%

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

16 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with stable non-segmental vitiligo * No new lesions * No enlargement of existing lesions * Patients of both sexes * Age 16 years or older

Exclusion criteria

* Active vitiligo * Pregnant or lactating women * History of keloid formation * Hematological disorders * Coagulopathies * Use of anticoagulant therapy * Use of medications that may prolong bleeding * Previous vitiligo treatment in the last 2 months

Design outcomes

Primary

Measure	Time frame
Repigmentation in the vitiliginous area after receiving the treatment and increasing the wnt b catenin marker level in the histopathological specimen	From enrollment to the end of treatment at 16 weeks for each patient

Contacts

CONTACTRasha Hesham el dein mohammed, Bachelor

rashahesham15@gmail.com+201111199719

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026